• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cytodyn Inc (OP: CYDY )

    0.1299 UNCHANGED
    Streaming Delayed Price Updated: 3:58 PM EDT, Aug 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.1299
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.1299
    Today's Range 0.1299 - 0.1299
    52wk Range 0.1110 - 0.4180
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CytoDyn Announces Settlement with Amarex Clinical Research LLC
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
    From CytoDyn Inc.
    Via GlobeNewswire

    Performance

    YTD
    -34.06%
    -34.06%
    1 Month
    -6.88%
    -6.88%
    3 Month
    -11.99%
    -11.99%
    6 Month
    -19.81%
    -19.81%
    1 Year
    -37.55%
    -37.55%

    More News

    Read More
    CytoDyn to Host Webcast to Provide Company Update
    From CytoDyn Inc.
    Via GlobeNewswire
    May 2024 Letter to Shareholders
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces FDA Has Lifted Clinical Hold
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Webcast to Provide Company Update
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
    From CytoDyn Inc.
    Via GlobeNewswire
    November 2023 Letter to Shareholders
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Company Updates and Investment Community Update Webcast
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces President Takes Medical Leave of Absence
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn to Hold Webcast to Provide a Company Update
    From CytoDyn Inc.
    Via GlobeNewswire
    Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
    Via Benzinga
    CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
    From CytoDyn Inc.
    Via GlobeNewswire
    OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
    Via Benzinga
    CytoDyn to Host R&D Update on Wednesday, December 7, 2022
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
    From CytoDyn Inc.
    Via GlobeNewswire
    Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
    Via Benzinga
    CytoDyn Announces Appointment of Additional Directors with Industry Experience
    From CytoDyn Inc.
    Via GlobeNewswire
    OTC Markets' Most Active Securities Sees A Shake-up In July
    Via Benzinga
    CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month
    Via Benzinga
    Mortgage Financiers & Crypto Securities Reclaim Their Spots As Most Actively Traded Securities On OTC Markets In June
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.